Centre de référence des microangiopathies thrombotiques
Accessibilité
Accueil 
Le centre CNR-MAT Publications du CNR
Le centre CNR-MAT Publications du CNRPublications du CNR
Sur cette page du centre de référence, vous pourrez trouver quelques informations plus spécifiques sur les missions et actions menées ainsi que les publications scientifiques émanant du centre.
- Présentation du centre de référence
- Les protocoles nationaux de diagnostic et de soins pour chacune des maladies dont s'occupe le centre
- Liste des actes et prestations (LAP HAS) dans le cadre du PNDS - HAS
Écrit par cnr-mat
le 31 Janvier 2023
Sous l'égide de MaRIH
Ce Protocole National de Diagnostic et Soins (PNDS) a été coordonné par le Pr Paul Coppo du Centre National de Référence des Microangiopathies Thrombotiques (Hôpital Saint-Antoine, Paris), en collaboration avec le Pr Agnès Veyradier (Hôpital Lariboisière, Paris) et le Pr Ygal Benhamou (Hôpital Charles-Nicolle, Rouen) sous l'égide de la filière de santé Maladies Rares Immuno-Hématologiques (MaRIH).
Ce document est soutenu par la Société Française d'Hématologie (SFH), la Société Nationale de Médecine Interne (SNFMI) et le Groupe Français d'Étude sur l'Hémostase et la Thrombose (GFHT)
Mis à jour le 26 Mars 2024
Écrit par Paul
le 01 Janvier 2023
ARTICLES EN ANGLAIS
How I treat thrombotic microangiopathy in the era of rapid genomics. Doreille A, et al. Blood. 2023 Jan 12;141(2):147-155.
Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura. Comparon C, Galicier L, Rebibou JM, Coppo P, Benhamou Y. Eur J Haematol. 2023 Feb;110(2):157-160. doi: 10.1111/ejh.13886. Epub 2022 Nov 14.
ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology. Joly BS, Roose E, Coppo P, Vanhoorelbeke K, Veyradier A. Haematologica. 2023 Feb 1;108(2):638-644. doi: 10.3324/haematol.2022.280768.
Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura. Joffre J, Raia L, Urbina T, Bonny V, Gabarre P, Missri L, Baudel JL, Coppo P, Guidet B, Maury E, Ait-Oufella H. Crit Care. 2023 Mar 21;27(1):116. doi: 10.1186/s13054-023-04405-w.
The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review. Joseph A, Joly BS, Picod A, Veyradier A, Coppo P. J Clin Med. 2023 Apr 23;12(9):3068. doi: 10.3390/jcm12093068.
Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity. Tellier E, Widemann A, Cauchois R, Faccini J, Lagarde M, Brun M, Robert P, Robert S, Bachelier R, Poullin P, Roose E, Vanhoorelbeke K, Coppo P, Dignat-George F, Kaplanski G. Haematologica. 2023 Apr 1;108(4):1127-1140. doi: 10.3324/haematol.2022.280651.
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Fillié-Grijpma YE, Raveling-Eelsing E, Graça NAG, Leijser T, Pas HH, Laura van Nijen-Vos L, Braham MVJ, Buisman AM, de Jong J, Schriek AI, Tio-Gillen AP, Teng YKO, Steenhuis M, Swaneveld FH, de Taeye SW, van Gils MJ, Verschuuren JJGM, Rutgers B, Heeringa P, Horváth B, Jacobs BC, de Leeuw K, Franssen CFM, Veyradier A, Coppo P, Gelderman KA, Marieke van Ham S, van Els CACM, van der Woude D, Huizinga R, Huijbers MG, Kuijpers TW, Toes REM, Bos NA, Rispens T; T2B Consortium. J Allergy Clin Immunol. 2023 Jun;151(6):1646-1654. doi: 10.1016/j.jaci.2022.10.035. Epub 2023 Jan 27.
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura. Picod A, Benhamou Y, Bouzid R, Veyradier A, Coppo P. Blood Adv. 2023 Jun 27;7(12):2678-2680. doi: 10.1182/bloodadvances.2022009021.
Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Neuman L, Joseph A, Bouzid R, Lescroart M, Mariotte E, Ederhy S, Tuffet S, Baudel JL, Benhamou Y, Galicier L, Grangé S, Provôt F, Neel A, Pène F, Delmas Y, Presne C, Poullin P, Wynckel A, Perez P, Barbet C, Halimi JM, Chatelet V, Rebibou JM, Ojeda-Uribe M, Vigneau C, Mesnard L, Veyradier A, Azoulay E, Coppo P, Chabriat H; participants to the Prospective Multicenter MATRISK study. J Neurol. 2023 Oct;270(10):5023-5033. doi: 10.1007/s00415-023-11830-y. Epub 2023 Jul 1.
Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura? Coppo P, Joly BS; French Reference Center for Thrombotic Microangiopathies (CNR-MAT). Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.
Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay. Bonnez Q, Dekimpe C, Tellier E, Kaplanski G, Verhamme P, Tersteeg C, De Meyer SF, Lammertyn J, Joly B, Coppo P, Veyradier A, Vanhoorelbeke K. Res Pract Thromb Haemost. 2023 Aug 19;7(6):102171. doi: 10.1016/j.rpth.2023.102171. eCollection 2023 Aug.
Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome. Azoulay E, Souppart V, Kentish-Barnes N, Benhamou Y, Joly BS, Zafrani L, Joseph A, Canet E, Presne C, Grall M, Zerbib Y, Provot F, Fadlallah J, Mariotte E, Urbina T, Veyradier A, Coppo P. J Crit Care. 2023 Aug;76:154283. doi: 10.1016/j.jcrc.2023.154283. Epub 2023 Mar 15.
High sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Pregnancy-Onset Thrombotic Thrombocytopenic Purpura. Béranger N, Tsatsaris V, Coppo P, Veyradier A, Joly BS. Hypertension. 2023 Sep;80(9):e140-e142. doi: 10.1161/HYPERTENSIONAHA.123.20987. Epub 2023 May 12.
Efficacy and Safety of Rituximab-Based Treatments in Angioedema With Acquired C1-Inhibitor Deficiency. Kalmi G, Nguyen Y, Amarger S, Aubineau M, Bibes B, Blanchard-Delaunay C, Boccon-Gibod I, Bouillet L, Coppo P, Dalmas MC, Debord-Peguet S, Defendi F, Demoreuil C, Du-Thanh A, Gayet S, Hadjadj J, Jeandel PY, Launay D, Ly KH, Avoy CM, Niault M, Ollivier Y, Pelletier F, Porneuf M, Roos-Weil D, Fain O, Gobert D. J Allergy Clin Immunol Pract. 2023 Oct 14:S2213-2198(23)01134-0. doi: 10.1016/j.jaip.2023.10.017.
The challenging follow-up of pregnancy in women with known thrombotic thrombocytopenic purpura: a single-center experience of a preemptive management protocol. Hamroun A, Prouteau C, Lenain R, Roger C, Bauters A, Zawadzki C, Subtil D, Gibier JB, Stichelbout M, Coppo P, Lionet A, Maanaoui M, Hazzan M, Provôt F. J Nephrol. 2023 Dec;36(9):2519-2529. doi: 10.1007/s40620-023-01790-x. Epub 2023 Oct 11.
Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpura. De Waele L, Sakai K, Mancini I, Sinkovits G, Falter T, Inoue T, Agosti P, Rossmann H, Von Auer C, Tersteeg C, De Meyer SF, Joly BS, Veyradier A, Coppo P, Fijnheer R, Peyvandi F, Prohászka Z, Lämmle B, Vanhoorelbeke K. J Thromb Haemost. 2023 Oct 20:S1538-7836(23)00783-3. doi: 10.1016/j.jtha.2023.10.014.
The Metamorphosis, struggling to adapt to a new condition. The lived experience of patients with Thrombotic microangiopathies diagnosed in the ICU. A qualitative study. Kentish-Barnes N, Souppart V, Cohen-Solal Z, Benhamou Y, Coppo P, Veyradier A, Azoulay E. J Crit Care. 2023 Dec;78:154366. doi: 10.1016/j.jcrc.2023.154366. Epub 2023 Jul 13.
Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura. Postmus T, Graça NAG, Ferreira de Santana J, Ercig B, Langerhorst P, Luken B, Joly BS, Vanhoorelbeke K, Veyradier A, Coppo P, Voorberg J. J Thromb Haemost. 2023 Dec;21(12):3402-3413. doi: 10.1016/j.jtha.2023.08.017. Epub 2023 Aug 25.
Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience. Béranger N, Coppo P, Tsatsaris V, Boisseau P, Provôt F, Delmas Y, Poullin P, Vanhoorelbeke K, Veyradier A, Joly BS. Blood Adv. 2024 Jan 9;8(1):183-193. doi: 10.1182/bloodadvances.2023011972.
Mis à jour le 03 Janvier 2024
Écrit par cnr-mat
le 31 Janvier 2022
Sous l’égide de la filière ORKiD et de la filière MaRIH
L’objectif de ce protocole national de diagnostic et de soins (PNDS) est d’expliciter aux professionnels concernés la prise en charge diagnostique et thérapeutique optimale actuelle et le parcours de soins d’un patient atteint de SHU. Il a pour but d’optimiser et d’harmoniser la prise en charge et le suivi de la maladie rare sur l’ensemble du territoire. Il permet également d’identifier les spécialités pharmaceutiques utilisées dans une indication non prévue dans l’Autorisation de Mise sur le Marché (AMM) ainsi que les spécialités, produits ou prestations nécessaires à la prise en charge des patients mais non habituellement pris en charge ou remboursés.
Mis à jour le 21 Mars 2024
Écrit par Paul
le 31 Décembre 2022
ARTICLES EN ANGLAIS
Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. Burguet L, Taton B, Prezelin-Reydit M, Rubin S, Picard W, Gruson D, Ryman A, Contin-Bordes C, Coppo P, Combe C, Delmas Y. J Clin Med. 2022 Jan 27;11(3):648. doi: 10.3390/jcm11030648.
TTP: From empiricism for an enigmatic disease to targeted molecular therapies. Graça NAG, Joly BS, Voorberg J, Vanhoorelbeke K, Béranger N, Veyradier A, Coppo P. Br J Haematol. 2022 Apr;197(2):156-170. doi: 10.1111/bjh.18040. Epub 2022 Feb 10.
Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination. Picod A, Rebibou JM, Dossier A, Cador B, Ribes D, Vasco-Moynet C, Stephan C, Bellal M, Wynckel A, Poullin P, Péju E, Ricard L, Kahn JE, Bouzid R, Benhamou Y, Joly B, Veyradier A, Coppo P. Blood. 2022 Apr 21;139(16):2565-2569. doi: 10.1182/blood.2021015149.
Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure. Joseph A, Eloit M, Azoulay E, Kaplanski G, Provot F, Presne C, Wynckel A, Grangé S, Rondeau É, Pène F, Delmas Y, Lautrette A, Barbet C, Mousson C, Coindre JP, Perez P, Jamme M, Augusto JF, Poullin P, Jacobs F, El Karoui K, Vigneau C, Ulrich M, Kanouni T, Le Quintrec M, Hamidou M, Ville S, Charvet-Rumpler A, Ojeda-Uribe M, Godmer P, Fremeaux-Bacchi V, Veyradier A, Halimi JM, Coppo P. Res Pract Thromb Haemost. 2022 May 18;6(4):e12702. doi: 10.1002/rth2.12702. eCollection 2022 May.
European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis. Eller K, Knoebl P, Bakkaloglu SA, Menne JJ, Brinkkoetter PT, Grandt L, Thiem U, Coppo P, Scully M, Haller MC. Nephrol Dial Transplant. 2022 Jun 23;37(7):1229-1234. doi: 10.1093/ndt/gfac034.
Predictive Scores for Early Identification of Immune-Mediated Thrombotic Thrombocytopenic Purpura: Room for Improvement? Joseph A, Brilland B, Burguet L, Eloit M, Fage N, Augusto JF, Delmas Y, Veyradier A, Halimi JM, Coppo P. Kidney Int Rep. 2022 Sep 23;7(11):2541-2542. doi: 10.1016/j.ekir.2022.09.016. eCollection 2022 Nov.
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. Scully M, de la Rubia J, Pavenski K, Metjian A, Knöbl P, Peyvandi F, Cataland S, Coppo P, Kremer Hovinga JA, Minkue Mi Edou J, De Passos Sousa R, Callewaert F, Gunawardena S, Lin J. J Thromb Haemost. 2022 Dec;20(12):2810-2822. doi: 10.1111/jth.15892. Epub 2022 Oct 21.
Mis à jour le 19 Mars 2024
Écrit par Paul
le 15 Janvier 2022
ARTICLES EN ANGLAIS
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP. De Waele L, Curie A, Kangro K, Tellier E, Kaplanski G, Männik A, Tersteeg C, Joly BS, Coppo P, Veyradier A, De Meyer SF, Roose E, Vanhoorelbeke K. Blood Adv. 2021 Sep 24:bloodadvances.2021004971.
Anti-ADAMTS13 autoantibody profiling in immune-mediated thrombotic thrombocytopenic purpura patients. Kangro K, Roose E, Joly BS, Sinkovits G, Falter T, von Auer C, Rossmann H, Reti M, Voorberg J, Prohászka Z, Lämmle B, Coppo P, Veyradier A, De Meyer SF, Männik A, Vanhoorelbeke K.Blood Adv. 2021 Sep 14;5(17):3427-3435.
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. Grall M, Daviet F, Chiche NJ, Provot F, Presne C, Coindre JP, Pouteil-Noble C, Karras A, Guerrot D, François A, Benhamou Y, Veyradier A, Frémeaux-Bacchi V, Coppo P, Grangé S. BMC Nephrol. 2021 Jul 21;22(1):267.
Shiga Toxin-Associated Hemolytic Uremic Syndrome in Adults, France, 2009-2017. Travert B, Dossier A, Jamme M, Cointe A, Delmas Y, Malot S, Wynckel A, Seguin A, Presne C, Hie M, Benhamou Y, Ribes D, Choukroun G, Grangé S, Hertig A, Le Gall EC, Galicier L, Daugas E, Bouadma L, Weill FX, Azoulay E, Fakhouri F, Veyradier A, Bonacorsi S, Hogan J, Frémeaux-Bacchi V, Rondeau E, Mariani-Kurkdjian P, Coppo P; Centre de Référence des Microangiopathies Thrombotiques2. Emerg Infect Dis. 2021;27(7):1876-1885.
Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era. Mirouse A, Legriel S, Dumas G, Labro G, Veyradier A, Zafrani L, Valade S, Hourmant Y, Boutboul D, Darmon M, Coppo P, Mariotte E, Azoulay E. Crit Care Med. 2021 Jun 24. doi: 10.1097/CCM.0000000000005164.
Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. Martis N, Jamme M, Bagnis-Isnard C, Pouteil-Noble C, Presne C, Vigneau C, Grangé S, Burtey S, Coindre JP, Wynckel A, Hamidou MA, Kanouni T, Azoulay E, Hié M, Chauveau D, Veyradier A, Rondeau E, Coppo P; French Reference Centre for Thrombotic Microangiopathies. Eur J Intern Med. 2021 Jun 23:S0953-6205(21)00199-0.
N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. Ercig B, Graça NAG, Kangro K, Arfman T, Wichapong K, Hrdinová J, Kaijen P, van Alphen FPJ, van den Biggelaar M, Vanhoorelbeke K, Veyradier A, Coppo P, Reutelingsperger C, Nicolaes GAF, Männik A, Voorberg J. Blood. 2021 May 13;137(19):2694-2698.
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. Blood Adv. 2021 Apr 27;5(8):2137-2141.
Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management. Travert B, Rafat C, Mariani P, Cointe A, Dossier A, Coppo P, Joseph A. Toxins (Basel). 2021 Apr 26;13(5):306.
Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases. Boudali J, Hallak B, Haeck M, Sellier-Leclerc AL, Ulrich M, Coppo P, Tellier S, Provôt F. J Nephrol. 2021 Feb 22. doi: 10.1007/s40620-021-00992-5.
Identification of a novel genetic locus associated with immune mediated thrombotic thrombocytopenic purpura. Stubbs MJ, Coppo P, Cheshire C, Veyradier A, Dufek S, Levine AP, Thomas M, Patel V, Connolly JO, Hubank M, Benhamou Y, Galicier L, Poullin P, Kleta R, Gale DP, Stanescu H, Scully MA. Haematologica. 2021 Feb 18. doi: 10.3324/haematol.2020.274639.
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. Alhenc-Gelas M, Cabel L, Berger F, Delaloge S, Frenel JS, Levy C, Firmin N, Ladoire S, Desmoulins I, Heudel PE, Dalenc F, Loirat D, Dubot C, Vuagnat P, Deluche E, Mokdad-Adi M, Patsouris A, Annic J, Djerroudi L, Lavigne M, Pierga JY, Coppo P, Bidard FC. Breast Cancer Res. 2021 Jan 19;23(1):9.
Mis à jour le 15 Janvier 2022
Voir aussi :
- Diplôme Universitaire [Article]
- Articles médicaux - 2020 [Article]
- Pandémie à COVID19 [Article]
- Articles médicaux - 2019 [Article]
Dernières actualités
- PTT congénital : La protéine ADAMTS13 recombinante bientôt disponible en accès précoce - publié le 26/03/24, [318 clics]
- Essais thérapeutiques en cours - publié le 12/02/24, [372 clics]
- Journée AD'venir 2023 - publié le 31/01/24, [424 clics]
- Relabellisation du CNR-MAT - publié le 10/01/24, [29123 clics]
- Réunion du Centre de Référence 2023 - publié le 01/02/23, [423 clics]
Le centre CNR-MAT
Publications du CNR
Copyright © 2005 - 2024 Centre de référence des microangiopathies thrombotiques.
Conception & Intégration : Bysens
Joomla! est un logiciel libre sous licence GNU/GPL.